<DOC>
	<DOC>NCT00903656</DOC>
	<brief_summary>The aim of this study is to evaluate the potential of a Lapatinib plus Caelyx combination therapy as an effective and safe therapeutic regimen with a favourable cardiotoxicity profile, in the treatment of metastatic breast cancer following failure of prior trastuzumab.</brief_summary>
	<brief_title>Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Female patients, age â‰¥ 18 years Advanced or metastatic breast cancer, histologically confirmed Documented HER2 overexpression (IHC 3+ and/or FISH positive) At least one measurable lesion according to RECIST criteria. Patients with boneonly lesions are not eligible for study entry Documented disease progression Patients may have no more than 1 line of palliative treatment, however prior therapies must include trastuzumab in adjuvant or metastatic setting Life expectancy of at least 12 weeks Performance status 01 Cardiac ejection fraction &gt;= 50% as measured by echocardiogram or MUGA scan Adequate hematology, liver and renal function Pregnant or lactating women Serious medical or psychiatric disorders that would interfere with the patient's safety or informed consent Severe cardiac disease (uncontrolled angina, arrhythmia, chronic heart failure (CHF) or cardiac disease requiring a device) Ejection fraction below the institutional normal limit Maximum cumulative dose of 360 mg/m2 for doxorubicin and 720 mg/m2 for epirubicin Active bacterial, viral or fungal infection Patients with clinically apparent brain metastases Positivity for HIV, Hepatitis B or C History of other malignancy; patients who have been diseasefree for 5 years Concurrent cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy) or concurrent treatment with an investigational drug or participation in another clinical trial Known hypersensitivity to the study drugs Lapatinib and Caelyx or their excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>Her2</keyword>
	<keyword>Lapatinib</keyword>
	<keyword>Caelyx</keyword>
	<keyword>cardiotoxic</keyword>
</DOC>